[
  {
    "ts": "2025-05-13T13:00:00+00:00",
    "headline": "GE HealthCare Announces FDA Approval of Pediatric Indication for Optison Ultrasound Enhancing Agent",
    "summary": "ARLINGTON HEIGHTS, Ill., May 13, 2025--GE HealthCare (Nasdaq: GEHC) today announced the U.S. Food and Drug Administration (FDA) has approved a pediatric indication for the company’s Optison™ (Perflutren Protein-Type A Microspheres Injectable Suspension, USP) ultrasound enhancing agent (UEA). This approval will help improve the clarity and diagnostic accuracy of echocardiograms in pediatric patients, giving cardiologists a fuller picture of ventricular function when assessing possible heart abnor",
    "url": "https://finance.yahoo.com/news/ge-healthcare-announces-fda-approval-130000323.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "d69fd565-ce4f-337b-b130-a54ef485ce68",
      "content": {
        "id": "d69fd565-ce4f-337b-b130-a54ef485ce68",
        "contentType": "STORY",
        "title": "GE HealthCare Announces FDA Approval of Pediatric Indication for Optison Ultrasound Enhancing Agent",
        "description": "",
        "summary": "ARLINGTON HEIGHTS, Ill., May 13, 2025--GE HealthCare (Nasdaq: GEHC) today announced the U.S. Food and Drug Administration (FDA) has approved a pediatric indication for the company’s Optison™ (Perflutren Protein-Type A Microspheres Injectable Suspension, USP) ultrasound enhancing agent (UEA). This approval will help improve the clarity and diagnostic accuracy of echocardiograms in pediatric patients, giving cardiologists a fuller picture of ventricular function when assessing possible heart abnor",
        "pubDate": "2025-05-13T13:00:00Z",
        "displayTime": "2025-05-13T13:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/e1b586e5eb977175cf591cf1c72cc9ca",
          "originalWidth": 480,
          "originalHeight": 320,
          "caption": "The U.S. FDA has approved GE HealthCare’s Optison™ (Perflutren Protein-Type A Microspheres Injectable Suspension, USP) ultrasound enhancing agent for use in pediatric patients.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hhfItu6KiGTzHdJR1amD7w--~B/aD0zMjA7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/e1b586e5eb977175cf591cf1c72cc9ca.cf.webp",
              "width": 480,
              "height": 320,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/XTxRATTnPkckzQhWNGlTTg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/e1b586e5eb977175cf591cf1c72cc9ca.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/ge-healthcare-announces-fda-approval-130000323.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/ge-healthcare-announces-fda-approval-130000323.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GEHC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-05-13T12:00:00+00:00",
    "headline": "GE HealthCare and Raydiant Oximetry accelerate innovation in fetal oxygen saturation technology",
    "summary": "CHICAGO & SAN RAMON, Calif., May 13, 2025--GE HealthCare (Nasdaq: GEHC) and Raydiant Oximetry, Inc. today announced a joint development initiative to enhance fetal monitoring capabilities that could strengthen the support of clinical decision-making during labor. This effort leverages the combined expertise and technology of the two companies to advance fetal oxygen saturation monitoring technology with the goal of enhancing the detection of fetal distress during childbirth.",
    "url": "https://finance.yahoo.com/news/ge-healthcare-raydiant-oximetry-accelerate-120000941.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "df7e3f7c-64df-39ec-bfd7-af03506bfd39",
      "content": {
        "id": "df7e3f7c-64df-39ec-bfd7-af03506bfd39",
        "contentType": "STORY",
        "title": "GE HealthCare and Raydiant Oximetry accelerate innovation in fetal oxygen saturation technology",
        "description": "",
        "summary": "CHICAGO & SAN RAMON, Calif., May 13, 2025--GE HealthCare (Nasdaq: GEHC) and Raydiant Oximetry, Inc. today announced a joint development initiative to enhance fetal monitoring capabilities that could strengthen the support of clinical decision-making during labor. This effort leverages the combined expertise and technology of the two companies to advance fetal oxygen saturation monitoring technology with the goal of enhancing the detection of fetal distress during childbirth.",
        "pubDate": "2025-05-13T12:00:00Z",
        "displayTime": "2025-05-13T12:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/9527fb3eced192d72c170586319d75e7",
          "originalWidth": 6570,
          "originalHeight": 2242,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/56xiWfhk6BS.akAbfusOMg--~B/aD0yMjQyO3c9NjU3MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/9527fb3eced192d72c170586319d75e7.cf.webp",
              "width": 6570,
              "height": 2242,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/WmXK3zeWKDMCA1qXNTIYsg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/9527fb3eced192d72c170586319d75e7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/ge-healthcare-raydiant-oximetry-accelerate-120000941.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/ge-healthcare-raydiant-oximetry-accelerate-120000941.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GEHC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]